CA2046598A1 - T-pa solubilisation - Google Patents

T-pa solubilisation

Info

Publication number
CA2046598A1
CA2046598A1 CA2046598A CA2046598A CA2046598A1 CA 2046598 A1 CA2046598 A1 CA 2046598A1 CA 2046598 A CA2046598 A CA 2046598A CA 2046598 A CA2046598 A CA 2046598A CA 2046598 A1 CA2046598 A1 CA 2046598A1
Authority
CA
Canada
Prior art keywords
activity
acid
protein
solubilisation
edta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2046598A
Other languages
French (fr)
Other versions
CA2046598C (en
Inventor
Ulrich Kohnert
Rainer Rudolph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2046598A1 publication Critical patent/CA2046598A1/en
Application granted granted Critical
Publication of CA2046598C publication Critical patent/CA2046598C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Lubricants (AREA)

Abstract

The invention relates to a pharmaceutical preparation of a protein with t-PA activity, with an enzymatic activity of at least 0.25 MU/ml and a pH of 4.5 to 9, containing a substance from the group citric acid, ascorbic acid, 2-oxoglutaric acid, fumaric acid, tris and EDTA in a concentration of at least 0.2 mol/l, and to a drug based on a protein with t-PA activity and a process for producing it.
CA002046598A 1989-12-20 1990-12-19 T-pa solubilisation Expired - Lifetime CA2046598C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3942145.7 1989-12-20
DE3942145A DE3942145A1 (en) 1989-12-20 1989-12-20 T-PA SOLUBILIZATION

Publications (2)

Publication Number Publication Date
CA2046598A1 true CA2046598A1 (en) 1991-06-21
CA2046598C CA2046598C (en) 1997-01-14

Family

ID=6395928

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002046598A Expired - Lifetime CA2046598C (en) 1989-12-20 1990-12-19 T-pa solubilisation

Country Status (11)

Country Link
EP (1) EP0458929B1 (en)
JP (1) JPH0657660B2 (en)
KR (1) KR920700683A (en)
AT (1) ATE102046T1 (en)
AU (1) AU625831B2 (en)
CA (1) CA2046598C (en)
DE (2) DE3942145A1 (en)
FI (1) FI95998C (en)
HU (2) HUT60133A (en)
NO (1) NO305582B1 (en)
WO (1) WO1991008764A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3942141A1 (en) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2P PRO STABILIZATION
WO2005072803A1 (en) 2004-01-16 2005-08-11 Biodel, Inc. Sublingual drug delivery device
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
GB8612868D0 (en) * 1986-05-27 1986-07-02 Mars G B Ltd Beverage packages
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (en) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh STABILIZATION OF GLYCOSYLATED T-PA

Also Published As

Publication number Publication date
FI95998C (en) 1996-04-25
WO1991008764A1 (en) 1991-06-27
KR920700683A (en) 1992-08-10
HU912740D0 (en) 1992-01-28
JPH04503680A (en) 1992-07-02
CA2046598C (en) 1997-01-14
NO912775L (en) 1991-07-15
EP0458929B1 (en) 1994-03-02
NO305582B1 (en) 1999-06-28
EP0458929A1 (en) 1991-12-04
AU625831B2 (en) 1992-07-16
DE59004814D1 (en) 1994-04-07
HUT60133A (en) 1992-08-28
DE3942145A1 (en) 1991-06-27
ATE102046T1 (en) 1994-03-15
HU208630B (en) 1993-12-28
AU6914991A (en) 1991-07-18
NO912775D0 (en) 1991-07-15
FI913907A0 (en) 1991-08-19
JPH0657660B2 (en) 1994-08-03
FI95998B (en) 1996-01-15

Similar Documents

Publication Publication Date Title
LTIP1652A (en) Protein, biologically active hormone, method for protein production, pharmaceutical preparation
UA43348C2 (en) Aqueous pharmaceutical composition, which includes the factor of the nerve growth factor (variants) and liophilic pharmaceutical composition
ZA96503B (en) Stable-lipid-comprising drug delivery complexes and methods for their production
DK0454898T3 (en) Glycosaminoglycan modified protein, method of producing the protein, pharmaceutical preparations containing the protein and use of the protein
DE3477137D1 (en) Aqueous solution containing lipid-soluble pharmaceutical substance and a process for preparing the same
HUT64595A (en) Method for producing mammalian cytokine, il-11
AU6701890A (en) Process for the production of biologically active protein
IL118201A0 (en) Erythropoietin free of animal proteins processes for production and use thereof
EP0233013A3 (en) Modified enzyme
EG19583A (en) Process for preparing pharmaceutical composition from chymopapain
AU5233686A (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
CA2046598A1 (en) T-pa solubilisation
ES8900018A1 (en) Rennin- and acid proteases-inhibitor peptidic amino alcohol derivatives, preparation process thereof and therapeutical application thereof.
CA2072797A1 (en) Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity
MY114693A (en) Substituted benzenesulfonylureas and thioureas,processes for their preparation,their use for the production of pharmaceutical preparations, and pharmaceutical preparation containing them
NO20003888L (en) Anti-enzyme preparations comprising ethylenediaminea succinic acid
HUT59610A (en) Process for producing pharmaceutical compositions for solving blood clot containing t-pa without glycosilyzing
NZ303133A (en) glycosylated human beta interferon
MY113432A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use for the production of pharmaceutical preparations, and medicaments containing them
EP0175323A3 (en) Biologically active peptides, processes for preparing them and pharmaceutical compositions
ES8406425A1 (en) Galenic form of amitriptyloxide, and process for its preparation.
Kohnert et al. Stabilized compositions having human tissue type plasminogen activator enzymatic activity
ATE105570T1 (en) MODIFIED HUMAN ANTI-RH(D) ANTIBODIES.
IE880198L (en) Plasminogen activator.
UA5743C2 (en) Preparation of biologically active tissue substances possessing regenerative activity and method for its production

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry